<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00776633</url>
  </required_header>
  <id_info>
    <org_study_id>GE IDE No. A01508</org_study_id>
    <nct_id>NCT00776633</nct_id>
  </id_info>
  <brief_title>Triple Therapy in Patients on Oral Anticoagulation After Drug Eluting Stent Implantation</brief_title>
  <acronym>ISAR-TRIPLE</acronym>
  <official_title>Intracoronary Stenting and Antithrombotic Regimen: Testing of a Six-week Versus a Six-month Clopidogrel Treatment Regimen in Patients With Concomitant Aspirin and Oral Anticoagulant Therapy Following Drug-eluting Stenting</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Deutsches Herzzentrum Muenchen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Deutsches Herzzentrum Muenchen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators hypothesize that reducing the duration of clopidogrel therapy from 6 months
      to 6 weeks after DES implantation is associated with improved clinical outcomes in patients
      on ASA and an oral anticoagulant.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The introduction of drug-eluting stents (DES) was associated not only with a widening of the
      indication for percutaneous coronary intervention (PCI) but also with longer antithrombotic
      therapy duration. Dual antiplatelet therapy with ASA and a thienopyridine is very efficient
      in preventing adverse events after coronary stenting but it is inferior to oral
      anticoagulation (OAC) to reduce the risk of stroke in patients with atrial fibrillation. OAC
      is also superior to antiplatelet therapy in patients with mechanical heart valves and the
      therapy of choice for the treatment of deep vein thrombosis and pulmonary embolism. OAC is
      also administered for left ventricular thrombi and low ejection fraction. There is an
      increasing number of patients undergoing coronary stenting who are in need of life-long
      anticoagulation therapy and would therefore require a triple therapy consisting of aspirin,
      clopidogrel and oral anticoagulation. As oral anticoagulation and antithrombotic therapy
      impair primary and secondary hemostasis there are concerns that adding warfarin to dual
      antiplatelet therapy might cause increased bleeding rates. Several studies have
      retrospectively assessed efficacy and safety in patients receiving a triple therapy with
      various results: major bleeding rates varied from 3,1%-14,9% with total bleeding rates up to
      27,5%. Prospective randomized data on this topic are not available. Therefore the aim of this
      study is to compare a 6 week versus a 6 month triple therapy after DES implantation.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>September 2008</start_date>
  <completion_date type="Anticipated">September 2014</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite of death, myocardial infarction, definite stent thrombosis, stroke or major bleeding.</measure>
    <time_frame>9 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ischemic complications (composite of cardiac death, myocardial infarction, stent thrombosis or ischemic stroke)</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding complications (Major bleeding)</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">614</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Short triple</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 weeks triple therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Long triple</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>6 months triple therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aspirin</intervention_name>
    <description>6 weeks triple therapy with aspirin, clopidogrel and oral anticoagulation</description>
    <arm_group_label>Short triple</arm_group_label>
    <arm_group_label>Long triple</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clopidogrel</intervention_name>
    <description>6 months triple therapy with aspirin, clopidogrel and oral anticoagulation</description>
    <arm_group_label>Short triple</arm_group_label>
    <arm_group_label>Long triple</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oral anticoagulation</intervention_name>
    <arm_group_label>Short triple</arm_group_label>
    <arm_group_label>Long triple</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          1. Patients with an indication for oral anticoagulation and a DES implantation.

          2. Informed, written consent by the patient or her/his legally-authorized representative
             for participation in the study.

        Key Exclusion Criteria:

          1. Age ≤18 years

          2. Previous stent thrombosis

          3. DES in left main
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adnan Kastrati, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Deutsches Herzzentum München</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stefanie Schulz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Deutsches Herzzentrum Muenchen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deutsches Herzzentrum München</name>
      <address>
        <city>Munich</city>
        <zip>80636</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1. Medizinische Klinik, Klinikum rechts der Isar</name>
      <address>
        <city>München</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Rubboli A, Halperin JL, Airaksinen KE, Buerke M, Eeckhout E, Freedman SB, Gershlick AH, Schlitt A, Tse HF, Verheugt FW, Lip GY. Antithrombotic therapy in patients treated with oral anticoagulation undergoing coronary artery stenting. An expert consensus document with focus on atrial fibrillation. Ann Med. 2008;40(6):428-36. doi: 10.1080/07853890802089786. Review.</citation>
    <PMID>18608125</PMID>
  </reference>
  <reference>
    <citation>Schömig A, Neumann FJ, Kastrati A, Schühlen H, Blasini R, Hadamitzky M, Walter H, Zitzmann-Roth EM, Richardt G, Alt E, Schmitt C, Ulm K. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med. 1996 Apr 25;334(17):1084-9.</citation>
    <PMID>8598866</PMID>
  </reference>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 20, 2008</study_first_submitted>
  <study_first_submitted_qc>October 20, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2008</study_first_posted>
  <last_update_submitted>August 29, 2016</last_update_submitted>
  <last_update_submitted_qc>August 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>aspirin</keyword>
  <keyword>clopidogrel</keyword>
  <keyword>oral anticoagulation</keyword>
  <keyword>warfarin</keyword>
  <keyword>drug eluting stent</keyword>
  <keyword>phenprocoumon</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

